| Hearken to this text |
Micro-robots are revolutionizing the delivery of medication within the human body through Endiatx’s pioneering innovation. The corporation’s flagship product, PillBot, is engineered to autonomously traverse the human abdominal cavity, thereby reducing costs and increasing access to diagnosis and treatment options.
The PillCam is poised to revolutionize endoscopy for tens of millions of patients, who currently undergo invasive procedures requiring annual exams using endoscopy scopes for physicians to visualize the intestinal tract’s inner lining. The device is engineered for remote control and ease of deployment, simplifying the process compared to inserting an endoscope.
See it stay
Will you be able to witness CEO Torrey Smith demonstrate PillBot live during the closing keynote session?
The transmitter stays submerged and broadcasts video because its propellers powerfully drive it through the water-filled abdominal cavity. Following an omitted meal, an individual who has been impacted experiences a craving for hydration and takes the prescribed PillBot with water. A robotic doctor operator, potentially detached from the patient, utilizes a controller and internet connection to guide the capsule through a scanning process that comprehensively examines the abdominal region. The device has a limited power supply, sufficient for approximately 30 minutes of video playback, and is intended as a single-use item, with users simply discarding it after completing their task. In response to CEO Torrey Smith, the invoice for the machine’s sole supply is priced at $35.
The Endiatax PillBot micro-robot is designed to precisely measure a single vitamin capsule. | Credit score: Endiatx
PillBot is expected to complete its medical trials by the end of 2024, with Endiatx anticipating FDA clearance for the device in 2025. The corporation anticipates a commercial launch in the United States by early 2026, followed by international development, focusing on emerging markets with limited access to healthcare facilities.
PillBot has the potential to revolutionize healthcare by significantly reducing the need for anesthesia and hospital stays while also minimizing insurance premiums, as an alarming 80% of high-endoscopy procedures yield unfavorable results. PillBot is engineered to significantly reduce invasiveness, allowing for a faster and more efficient process. Diagnostic procedures conducted by PillBot and its AI-driven descendants will detect illnesses exhibiting symptoms akin to abdominal cancer – a condition that claims approximately 800,000 lives worldwide annually – at an early stage, thereby enabling timely interventions and saving lives.
Currently, Endiatx boasts a team of 20 dedicated professionals and has secured $7 million in funding since its inception in 2019.
